4 Singapore REITs to Watch Out for in June
The REIT sector continues to be a reliable source of dividends for income investors who are seeking to navigate a complex macroeconomic landscape.
Although the asset class was beset by the twin challenges of inflation and elevated interest rates, things are looking up.
Interest rates have moderated, and inflation has declined significantly from its high in 2022.
Meanwhile, REIT managers have been active in reconstituting their portfolios and are engaging in capital recycling activities to improve their portfolios.
Here are four Singapore REITs you should keep an eye out for in June.
CapitaLand Ascendas REIT, or CLAR, is Singapore's oldest industrial REIT and also one of the largest industrial REITs listed on the Singapore Exchange (SGX: S68).
The REIT released an encouraging business update for the first quarter of 2025 (1Q 2025).
Portfolio occupancy stood at 91.5%, and the portfolio also enjoyed a positive rental reversion of 11%.
During the quarter, CLAR completed the sale and leaseback acquisition of a Class A modern logistics property for S$153.4 million.
A redevelopment at Science Park Drive was also completed for S$300 million.
The REIT also saw two asset enhancement initiatives (AEIs) completed, one in the US and the other in Singapore.
Just last week, CLAR announced the acquisition of two properties in Singapore – a data centre at 9 Tai Seng Drive, and a business space property at 5 Science Park Drive.
Both properties are fully occupied, with the data centre sporting a net property income (NPI) yield of 7.2% and the business space property having a 6.1% NPI yield.
These acquisitions will help to solidify the REIT's Singapore footprint and enhance the quality of CLAR's portfolio.
The purchases should also translate into a 1.36% accretion to distribution per unit (DPU) for the REIT.
Moreover, there is the potential for rental uplift as 9 Tai Seng Drive has room for capacity expansion.
For 5 Science Park Drive, the existing rent is around 15% below market rates, allowing for future positive rental reversion.
Mapletree Industrial Trust, or MIT, is an industrial REIT with a portfolio of 141 properties spanning 25.2 million square feet of net lettable area.
MIT's portfolio was valued at S$9.1 billion as of 31 March 2025.
In the middle of May, the REIT entered into a sale and purchase agreement to sell three industrial properties in Singapore for S$535.3 million to Brookfield Asset Management (NYSE: BAM).
These three properties, named The Strategy, The Synergy, and the Woodlands Central Cluster, were at a 2.6% premium to the properties' independent valuations of S$521.5 million.
It was also a 22.1% increase from these properties' original cost of S$438.4 million.
The Strategy and The Synergy had occupancy rates of 82.1% and 71.6%, respectively, while Woodlands Central boasted a higher occupancy rate of 95.5%.
These divestments should be completed by 3Q 2025.
MIT's rationale for the sale was to strengthen its capital structure and improve its financial flexibility for future investments while realising the capital appreciation on these properties.
Manulife US REIT, or MUST, is an office REIT with a portfolio of eight freehold properties in the US with a total NLA of 4.1 million square feet.
The office REIT agreed to sell its Peachtree Class A office building in Georgia for a gross consideration of around US$133.8 million.
MUST will receive around US$118.8 million in net proceeds, which will be used to make an early repayment of its 2026 loans.
With this repayment, around 78% of its total debt due in 2026 will be repaid.
This sale also allows MUST to achieve 82% of its net sales proceeds target under the Master Restructuring Agreement (MRA), enabling the beleaguered office REIT to negotiate a recovery path with its lenders.
The REIT had already divested Capitol in California and Plaza in New Jersey as part of its progress in repaying its loans.
With this divestment, MUST's pro-forma aggregate leverage should improve from 60.8% to 57.7%, with its pro-forma weighted average cost of debt reduced from 4.53% to 4.07%.
This disposal means that the REIT's portfolio will now comprise seven properties with an NLA of around 3.5 million square feet.
Elite UK REIT owns mostly freehold properties in the UK and is the largest provider of infrastructure to the Department for Work and Pensions (DWP) and other UK government departments.
As of 31 December 2024, the REIT had an AUM of more than S$2 billion.
Elite UK REIT reported an encouraging set of earnings for 1Q 2025 as revenue inched up 0.6% year on year to £9.3 million.
NPI shot up 24.4% year on year to £10.4 million because of a one-off lease surrender premium and dilapidation settlement.
Excluding this, NPI would have increased by 4.9% year on year to £8.7 million.
DPU increased by 9.6% year on year to £0.0076.
With its expanded investment mandate, the manager plans to reposition two of its properties.
The first is Lindsay House in Dundee, a vacant asset that can be repositioned into a purpose built-student accommodation (PBSA).
The conversion will use the property's existing structure, which will reduce project costs and accelerate the asset's time-to-market.
The expected opening of this PBSA is September 2027.
The other asset is a site in Blackpool, which can be developed into a potential data asset development.
Elite UK REIT has submitted the planning permission for this site, which is now in its final stages.
Looking to create a lifelong income stream? Check out our report, '7 Singapore Blue-Chip Stocks That Can Pay You for Life.' We uncover a powerful lineup of dividend-paying stocks with the reliability and growth potential you need in today's market. Don't miss out on these dependable picks. Download your copy now and start building a secure financial future!
Follow us on Facebook and Telegram for the latest investing news and analyses!
Disclosure: Royston Yang owns shares of Mapletree Industrial Trust and Singapore Exchange.
The post 4 Singapore REITs to Watch Out for in June appeared first on The Smart Investor.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Big Idea Ventures and Mars Petcare Launch 2025 Global Pet Food Innovation Program in Collaboration with AAK, Bühler, and Givaudan
Building on the success of last year's program, the second round aims to find the next cohort of trailblazers who can deliver innovation in the sustainable pet food space. Startups from around the world are invited to apply, with selected participants to showcase their solutions at the Asia-Pacific Agri-Food Innovation Summit. The program continues to unite leading food and pet care experts to accelerate sustainable pet food innovation. New York, NY , June 03, 2025 (GLOBE NEWSWIRE) -- Following the success of last year's program, Big Idea Ventures and Mars Petcare will launch the second round of the Next Generation Pet Food Program, in collaboration with AAK, Bühler, and Givaudan. This initiative aims to accelerate sustainable innovation in the pet food sector by supporting startups with novel ingredients, sustainable fats and proteins, and advanced processing technologies. Mars is exploring alternative ingredients in its pet food products to create more sustainable, future-ready nutrition. As consumer preference evolves Mars is working to give pet parents the opportunity to make more environmentally conscious choices, while taking steps to reduce its own carbon footprint. This year, Givaudan, a global leader in taste and wellbeing, joins AAK and Bühler as a collaborator, offering expertise in ingredient innovation and product development for humans and pets. Andrew D. Ive, Founder and Managing General Partner of Big Idea Ventures, stated:"Working with Mars last year was fantastic! We want to take the learnings and implement them on a big scale as we continue to search for and develop sustainable solutions for the pet food ecosystem. Last year, the teams from Mars Petcare, Bühler, and AAK offered invaluable insights to our startups. Now, by integrating Givaudan into the mix, we will further enhance the resources available to the startups we choose.' Paul Gardner, Commercial VP, Mars Pet Nutrition added: 'We must invest in innovation to help us source the best ingredients and build a future where the planet stays healthy, and where people and their pets are thriving. We're excited to be launching the second round of this program harnessing the creativity of startups, alongside partners that share our vision' 'We were thrilled at the enthusiastic response we got from last's program. It is a testament that innovative startups are the driving force behind the future of sustainable pet nutrition. The program offers a unique opportunity for visionary entrepreneurs to collaborate with leading industry experts, access state-of-the-art technology, and accelerate their impact on the global petfood market. I encourage all startups with bold ideas and a passion for transformation to apply and help us shape a healthier, more sustainable future for pets and planet alike,' said Dr. Ian Roberts, CTO at Bühler Group. Niall Sands, President Commercial Innovation and Development, AAK, shared that the company is excited to support pet food innovators to bring nutrition and health-promoting functionality to our beloved pets. They look forward to exploring how innovation in this space is helping pet parents support and care for our 4-legged family members. Fabio Campanile, Global Head of Science & Technology, Givaudan Taste & Wellbeing, noted, 'Givaudan is excited to be part of this program as it presents a unique opportunity to collaborate with innovative startups and partners, paving the way for a more sustainable and enriching world for pets. We look forward to building on our current capabilities in the pet food space as well as exploring new technologies.' Companies selected for the program will benefit from expert guidance, potential commercial partnerships, and the opportunity to showcase their solutions on a global stage at Asia-Pacific Agri-Food Innovation Summit in Singapore from November 4–6, 2025. Winners of the 2024 Global Pet Food Innovation Program include BiomeMega, Anomaly Bio, KIDEMIS, String Bio Private Limited, MiAlgae, who have been under the mentorship of Big Venture Idea, Mars, AAK and Bühler. The startups have gained insights from top pet food experts and collaborated with leading CPG, ingredient, and technology companies to further develop their concepts with the potential to develop future long-term collaborations. The program is open to startups from around the world, with a strong preference for scalable solutions that can demonstrate real-world impact and sustainability. While APAC-based startups are preferred, companies from all geographies are encouraged to apply. For more information, visit Interested startups are encouraged to apply here as early as possible and will be able to do so until July 16. Media contacts: Bühler: Dalen Jacomino Panto, Media Relations Manager Bühler AG, 9240 Uzwil, Switzerland Phone: +41 71 955 37 57 Mobile: +41 79 900 53 88 E-mail: Katja Hartmann, Media Relations ManagerBühler AG, 9240 Uzwil, Schweiz Mobile: +41 79 483 68 07 E-mail: Jeff Peppet, Content and Communications Director, T&W +1 513 293 3740AAK: Carl Ahlgren Head of Investor Relations and Corporate Communication IR, Communications and Brand Malmo, Sweden +46706810734 Alex Lloyd, Global R&D Communications Senior Manager Email: Idea Ventures: 259 Nassau St Ste 2, #1292 Princeton, NJ 08542 Shruti Salkar Email: news@ the Partners Big Idea Ventures Big Idea Ventures is the leading investor in food and agri technology globally. As one of the most active investors in the food-tech, agri-tech, and materials science sectors, we focus on identifying and investing in the most innovative and sustainable technology companies around the world. We collaborate with universities for tech transfer and by combining capital, knowledge, and partnerships, we drive economic growth and help to create food ecosystems. Our collaborations with leading corporations and governments aim to support entrepreneurs, scientists, and engineers in solving some of the world's biggest challenges. Big Idea Ventures has teams in New York, Paris and Asia and has invested in more than 120 companies across 30 countries. Incorporated Mars, Incorporated is driven by the belief that the world we want tomorrow starts with how we do business today. As a $50bn+ family-owned business, our diverse and expanding portfolio of leading pet care products and veterinary services support pets all around the world and our quality snacking and food products delight millions of people every day. We produce some of the world's best-loved brands including ROYAL CANIN®, PEDIGREE®, WHISKAS®, CESAR®, DOVE®, EXTRA®, M&M'S®, SNICKERS® and BEN'S ORIGINAL™. Our international networks of pet hospitals, including BANFIELD™, BLUEPEARL™, VCA™ and ANICURA™ span preventive, general, specialty, and emergency veterinary care, and our global veterinary diagnostics business ANTECH® offers breakthrough capabilities in pet diagnostics. The Mars Five Principles — Quality, Responsibility, Mutuality, Efficiency and Freedom — inspire our 150,000 Associates to act every day to help create a better world for people, pets and the planet. Everything AAK does is about Making Better Happen™. We specialize in plant-based oils and fats, the value-adding ingredients in many products people love to consume. We make these products better tasting, healthier, and more sustainable. At the heart of AAK's offer is Customer Co-Development, combining our desire to understand what Making Better Happen™ means for each customer, with the unique flexibility of our production assets, and deep knowledge of products and industries, including Chocolate & Confectionery, Bakery, Dairy, Plant-based Foods, Special Nutrition, Foodservice, and Personal Care. Our 4,100 employees support our close collaboration with customers through 25 regional sales offices, 16 dedicated Customer Innovation Centers, and with the support of more than 20 production facilities. Listed on Nasdaq Stockholm and headquartered in Malmö, Sweden, AAK has been Making Better Happen™ for more than 150 years. Bühler is driven by its purpose of creating innovations for a better world, balancing the needs of economy, humanity, and nature in all its decision-making processes. Billions of people come into contact with Bühler technologies as they cover their basic needs for food and mobility every day. Two billion people each day enjoy foods produced on Bühler equipment; and one billion people travel in vehicles manufactured using parts produced with Bühler solutions. Countless people wear eyeglasses, use smartphones, and read newspapers and magazines – all of which depend on Bühler process technologies and solutions. Having this global relevance, Bühler is in a unique position to turn today's global challenges into sustainable business. As a technology partner for the food, feed, and mobility industries, Bühler has committed to having solutions ready to multiply by 2025 that reduce energy, waste, and water by 50% in the value chains of its customers. It also proactively collaborates with suppliers to reduce climate impacts throughout the value chain. In its own operations, Bühler has developed a pathway to achieve a 60% reduction of greenhouse gas emissions by 2030 (Greenhouse Gas Protocol Scopes 1 & 2, against a 2019 baseline). Bühler spends up to 5% of turnover on research and development annually to improve both the commercial and sustainability performance of its solutions, products, and services. In 2023, some 12,500 employees generated a turnover of CHF 3.0 billion. As a Swiss family-owned company with a history spanning 164 years, Bühler is active in 140 countries around the world and operates a global network of 105 service stations, 30 manufacturing sites, and Application & Training Centers in 25 locations. Givaudan is a global leader in Fragrance & Beauty and Taste & Wellbeing. We celebrate the beauty of human experience by creating happier, healthier lives with love for nature. Together with our customers, we deliver food experiences, craft inspired fragrances, and develop beauty and wellbeing solutions that make people look and feel good. From your favourite drink to your daily meal, from prestige perfumes to laundry care, our products help people live happier and healthier lives, and we create them in a way that respects natural resources and the environment.
Yahoo
an hour ago
- Yahoo
Asia-Pacific NIPT Market to Hit USD 4.57 Billion by 2033: Growth Driven by Technological Advancements and Healthcare Reforms
Developed countries like Japan and South Korea have integrated NIPT into healthcare systems, while emerging markets like China and India are witnessing rapid adoption due to improved healthcare access and insurance reforms Asia-Pacific Non-Invasive Prenatal Testing Market Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Non-Invasive Prenatal Testing Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to offering. The Asia-Pacific Non-Invasive Prenatal Testing Market is expected to reach US$ 4.57 billion by 2033 from US$ 1.33 billion in 2024, with a CAGR of 14.64% from 2025 to 2033. The market is expanding due to factors such the demand for precise and prompt prenatal diagnoses, the usage of advanced genetic technology, and the aging of mothers. The introduction of healthcare reforms in several Asia-Pacific countries and the extension of insurance coverage for prenatal care are further encouraging the usage of NIPT. The non-invasive prenatal testing (NIPT) market in Asia-Pacific is expanding quickly due to factors including growing mother age, improved genetic testing technology, and growing awareness of prenatal care. Asia-Pacific, one of the most populated and varied regions, is home to nations with a range of socioeconomic backgrounds and healthcare infrastructure levels. This discrepancy has made NIPT adoption both difficult and possible. NIPT is becoming a common component of prenatal treatment in nations with highly developed healthcare systems, such as South Korea, Singapore, and Japan, especially for high-risk pregnancies. Meanwhile, as healthcare access improves and more women look for safer, more accurate screening alternatives, the demand for NIPT is rising quickly in emerging areas like China, India, and Southeast Asia. The Asia-Pacific region's more developed nations have robust healthcare systems, supportive governments, and high public awareness, all of which contribute to the NIPT industry. Due to its integration into national screening programs for high-risk pregnancies, NIPT is widely available and reasonably priced. Effective use of NIPT to identify chromosomal abnormalities and guide pregnancy treatment is ensured by the availability of qualified genetic counselors and established medical procedures. Technological advancements and the accessibility of sophisticated screening techniques in these areas further propel market growth. Less developed regions of the Asia-Pacific still face difficulties, nevertheless. NIPT is still a luxury service that is expensive and scarce in nations with inadequate healthcare resources or where healthcare systems are still developing. Barriers to broader acceptability also include ethical issues about genetic screening and cultural views on prenatal testing. Therefore, it is necessary to overcome both cultural opposition and infrastructure constraints in order to expand the NIPT market in these nations. For NIPT to become more widely available and reasonably priced throughout the Asia-Pacific region, it will be essential to maintain investments in healthcare infrastructure, public awareness initiatives, and legislative backing. The high cost of these tests, leading to relatively low affordability in many developing countries, will limit their adoption. According to an article published by Future Medicine, the average cost of non-invasive prenatal testing in India is around USD 350 to USD 400. According to an article published by the Australian Broadcasting Corporation in May 2022, an NIPT costs around USD 500 and is a high out-of-pocket cost during pregnancy, pressuring families to terminate their pregnancies after the first positive test for Down's syndrome. This has limited their uptake in emerging countries. Growth Drivers for the Asia-Pacific Non-Invasive Prenatal Testing Market Advancements in Genetic Testing Technology Non-invasive prenatal testing (NIPT) is now much more accurate, quick, and affordable because to developments in genetic testing technology, especially next-generation sequencing (NGS) and bioinformatics. Rapid fetal DNA analysis from maternal blood samples is made possible by NGS, which improves the test's sensitivity and specificity, particularly for identifying chromosomal disorders like Down syndrome. Advances in bioinformatics enable the rapid processing of enormous volumes of genetic data, cutting down on testing expenses and time. Because of these technical developments, NIPT is now more widely available to pregnant mothers in both developed and growing Asia-Pacific economies. As a result, NIPT is becoming more widely used worldwide, providing safer and more precise prenatal screening alternatives. Government Support and National Screening Programs The expansion of non-invasive prenatal testing (NIPT) throughout Asia is mostly due to government assistance and national screening initiatives. Because NIPT has been included into national healthcare systems in nations like Singapore and Japan, expecting moms may easily obtain and use it. These countries lower the dangers associated with intrusive testing techniques while also improving early diagnosis of chromosomal abnormalities by providing NIPT as part of standard prenatal care. Furthermore, NIPT's wider acceptability is facilitated by public health campaigns that inform patients of its advantages. Government support makes NIPT a dependable and crucial instrument in prenatal care throughout the area by helping to standardize its usage. Expansion of Private Healthcare A wider population now has far better access to non-invasive prenatal testing (NIPT) because to the growth of private healthcare providers in nations like Thailand and India. Private healthcare institutions provide advanced testing alternatives, such as NIPT, that might not be available in public systems because to the growing need for quicker and more thorough care. This expansion is especially helpful for pregnant moms who want more individualized care or faster outcomes. A greater variety of patients may now get sophisticated prenatal screening as private healthcare providers increase NIPT's accessibility and price, therefore closing the wealth gap between high- and middle-income groups. Additionally, this growth promotes healthy competition, which raises the standard and effectiveness of prenatal care. Challenges in the Asia-Pacific Non-Invasive Prenatal Testing Market Inconsistent Regulation and Standardization The Asia-Pacific non-invasive prenatal testing (NIPT) industry has major obstacles due to inconsistent legislation and standards. Different nations have different NIPT regulatory frameworks, which causes variations in certification, quality assurance, and testing procedures. The accuracy and dependability of results may be impacted in some areas by inadequate laboratory oversight or unclear test process recommendations. The safety and efficacy of the tests may be questioned as different nations may provide NIPT services of varying quality in the absence of uniform rules. This discrepancy can erode patient faith in NIPT, particularly in nations with laxer regulations, which would prevent the technique from being widely adopted and trusted. Infrastructure Challenges in Emerging Markets Non-invasive prenatal testing (NIPT) may not be widely available in developing nations with underdeveloped healthcare systems, especially in rural or isolated places. Modern medical facilities and specialist labs, which are usually concentrated in metropolitan areas, are frequently necessary for the availability of NIPT. Therefore, access to this advanced prenatal screening may be severely hampered for pregnant moms in impoverished or rural areas. Due to limited availability to NIPT, a sizable portion of the population is unable to take advantage of early genetic abnormality diagnosis. Investment in medical facilities, better diagnostic service distribution, and efforts to increase access to NIPT in less accessible areas are all necessary to address these infrastructural issues and guarantee more equal access to healthcare. Key Attributes Report Attribute Details No. of Pages 200 Forecast Period 2024-2033 Estimated Market Value (USD) in 2024 $1.4 Billion Forecasted Market Value (USD) by 2033 $4.58 Billion Compound Annual Growth Rate 14% Regions Covered Asia-Pacific Key Topics Covered1. Introduction2. Research Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Asia-Pacific Non-Invasive Prenatal Testing Market6. Market Share Analysis6.1 Component6.2 Application6.3 End User7. Asia-Pacific - Countries Non-Invasive Prenatal Testing Market7.1 China7.2 Japan7.3 India7.4 Australia7.5 South Korea7.6 Thailand7.7 Malaysia7.8 Indonesia7.9 New Zealand8. Component8.1 Instruments8.2 Kits and Reagents8.3 Services9. Application9.1 Down Syndrome (trisomy 21)9.2 Edwards Syndrome (trisomy 18)9.3 Patau Syndrome (trisomy 13)9.4 Turner Syndrome9.5 Other Applications10. End User10.1 Hospitals10.2 Diagnostic Labs11. Porter's Five Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players Analysis13.1 Eurofins Scientific13.1.1 Overview13.1.2 Key Persons13.1.3 Recent Development & Strategies13.1.4 Financial Insight13.2 F. Hoffmann-La Roche Ltd.13.3 Invitae Corporation13.4 Illumina Inc.13.5 Natera Inc.13.6 Centogene N.V.13.7 Qiagen For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Asia-Pacific Non-Invasive Prenatal Testing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
3 hours ago
- Yahoo
5 Reasons to Buy Realty Income Stock Right Now
Realty Income is a large and diversified net-lease real estate investment trust (REIT). The REIT has an above-average yield. Realty Income has a long track record of putting investors first. 10 stocks we like better than Realty Income › Realty Income (NYSE: O) is a foundational stock that can be the backbone of a diversified dividend portfolio. Most income-focused investors should at least consider adding it to their holdings. Here's a look at five key reasons right now is the time to buy this real estate investment trust (REIT). The S&P 500 index (SNPINDEX: ^GSPC) is yielding about 1.3% today. The average REIT has a yield of 4.1%. Realty Income's dividend yield is roughly 5.7%. Very clearly, it is providing investors with more income than many other options. That said, its yield is also toward the high end of its range during the past decade. It not only looks attractive relative to other options, but the REIT's yield also looks attractive relative to its own history. Just having a high yield isn't enough to make a dividend stock a buy. Sometimes a high yield is a sign that the dividend isn't sustainable. But when it comes to providing investors with a sustainable and growing dividend, Realty Income looks like a winner. It has increased its payout annually for three decades and counting. Within that streak is a run of 110 quarterly increases. This is a business that is designed to reward investors with reliable dividend growth. To be fair, the average annualized increase of the past 30 years was a modest 4% or so. That, however, is just slightly faster than the historical rate of inflation, which means the buying power of its payout is increasing over time. The company's property focus is on single-tenant net lease assets. A net lease requires the tenant to pay for most property-level operating costs. While any single property is high risk, since there's only one tenant, Realty Income owns 15,600 properties. The risk here is low because most tenants keep paying rent. Realty Income isn't the just the biggest in this niche, it is also highly diversified. Roughly 75% of its rents come from retail properties, with the remainder in industrial assets and a broad "other" category. (More on that below.) Unlike many of its peers, however, Realty Income isn't confined to the U.S. It has expanded into Europe, where the net lease model is still underutilized. Its giant portfolio and broad reach work together to support slow and steady dividend growth, because the REIT can take on deals that its peers couldn't manage. That includes large portfolio transactions and acting as an industry consolidator. Being able to absorb large deals is more than just a size issue. It also requires access to capital. Luckily, being a large company makes it easier to sell stock and debt. So Realty Income has an advantage on that front, too. But it doesn't take that for granted; it has worked to ensure it has an investment-grade balance sheet. That way, when it does go to the markets looking for cash, buyers provide it with attractive terms. An attractive cost of capital lets Realty Income bid aggressively for new properties while still being able to make a healthy profit. The "other" category noted above is important. It includes assets like casinos and data centers, where the REIT is starting to explore new investments. Management is also starting to include loans in its mix and is beginning to provide net-lease asset management services to institutional investors. These are all additional irons in the fire to support long-term growth. But the really exciting aspect here is that Realty Income is being innovative and experimenting with new investments. It is using what it does well -- net leases -- and expanding in new ways. To some extent, its size requires this approach, given that it takes more to move the needle on the top and bottom line as a company grow larger. But still, the fact that Realty Income is steadily working to maintain its dominance is a sign of management strength. And it helps set up the company and its investors for future dividend increases. This list started with dividend yield, and it will end with dividend yield because that's what income investors are looking for. But as noted, having a high yield, like Realty Income does, isn't enough to make a stock a buy. Reasons Nos. 2 through 5 help cement the deal, with this entrenched industry giant offering a value proposition that few can match. Right now is a good time to buy if you are looking to add an attractive dividend stock to your portfolio. Before you buy stock in Realty Income, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Realty Income wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Reuben Gregg Brewer has positions in Realty Income. The Motley Fool has positions in and recommends Realty Income. The Motley Fool has a disclosure policy. 5 Reasons to Buy Realty Income Stock Right Now was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data